Top-News
  • Depot
  • Watchlist
  • Glocke
  • Handeln

    • Shield Therapeuteutics plc News

    0,0163 € 0,00% +0,00 €
    30.04.24 22:58:42 L&S RT aktualisieren | Orderbuch | Mehr Kurse »
    WKN: A2AE98
    ISIN: GB00BYV81293
    US-Symbol: SHIEF
    Typ: Aktie

    Shield Therapeuteutics plc News

    15.11.23 - DGAP
    Hardman & Co Research on Shield Therapeutics (STX): Accelerating effectiveness of enlarged sales team
    Hardman & Co Research Hardman & Co Research on Shield Therapeutics (STX): Accelerating effectiveness of enlarged sales team 15-Nov-2023 / 07:30 GMT/BST The issuer is ...
    25.07.23 - DGAP
    Hardman & Co Research on Shield Therapeutics (STX): Accrufer Rx momentum gathering
    Hardman & Co Research Hardman & Co Research on Shield Therapeutics (STX): Accrufer Rx momentum gathering 25-Jul-2023 / 09:45 GMT/BST The issuer is solely responsible ...
    17.05.23 - DGAP
    Hardman & Co Research on Shield Therapeutics (STX): Reassuring 1Q’23 Accrufer prescriptions
    Hardman & Co Research Hardman & Co Research on Shield Therapeutics (STX): Reassuring 1Q’23 Accrufer prescriptions 17-May-2023 / 07:15 GMT/BST The issuer is solely ...
    23.01.23 - DGAP
    Hardman & Co Q&A on Shield Therapeutics (STX): Positioned for profitability with Viatris deal and its additional capital
    Hardman & Co Research Hardman & Co Q&A on Shield Therapeutics (STX): Positioned for profitability with Viatris deal and its additional capital 23-Jan-2023 / 11:15 GMT/BST ...
    13.01.23 - DGAP
    Hardman & Co Research: Shield Therapeutics (STX) - Positioned for growth and profitability
    Hardman & Co Research Hardman & Co Research: Shield Therapeutics (STX) - Positioned for growth and profitability 13-Jan-2023 / 07:15 GMT/BST Hardman & Co Research on ...
    15.09.22 - DGAP
    Hardman & Co Research on Shield Therapeutics (STX): Accrufer momentum building
    Hardman & Co Research Hardman & Co Research on Shield Therapeutics (STX): Accrufer momentum building 15-Sep-2022 / 13:52 GMT/BST Hardman & Co Research on Shield ...
    12.08.22 - DGAP
    Hardman & Co: Q&A on Shield Therapeutics (STX): Upside potential is enormous
    Hardman & Co Research Hardman & Co: Q&A on Shield Therapeutics (STX): Upside potential is enormous 12-Aug-2022 / 11:45 GMT/BST Hardman & Co Video | Analyst interview ...
    26.07.22 - DGAP
    Hardman & Co Research: Shield Therapeutics (STX): Looking to accelerate positive signals in the US
    Hardman & Co Research Hardman & Co Research: Shield Therapeutics (STX): Looking to accelerate positive signals in the US 26-Jul-2022 / 07:15 GMT/BST Hardman & Co ...
    02.03.22 - DGAP
    Hardman & Co Research: Shield Therapeutics (STX) - PBMs have bought in to Accrufer
    Hardman & Co Research Hardman & Co Research: Shield Therapeutics (STX) - PBMs have bought in to Accrufer 02-March-2022 / 13:30 GMT/BST Hardman & Co Research on ...
    07.10.21 - DGAP
    Hardman & Co Research: Shield Therapeutics (STX) Life Sciences Investor Forum research
    Hardman & Co Research Hardman & Co Research: Shield Therapeutics (STX) Life Sciences Investor Forum research 07-Oct-2021 / 09:45 GMT/BST Hardman & Co Life Sciences ...
    20.08.21 - DGAP
    Hardman & Co Research: Shield Therapeutics (STX) - Focused on US market penetration
    Hardman & Co Research Hardman & Co Research: Shield Therapeutics (STX) - Focused on US market penetration 20-Aug-2021 / 11:08 GMT/BST Hardman & Co Research ...
    12.08.21 - DGAP
    Hardman & Co Video Event | Shield Therapeutics plc - Investor Forum
    Hardman & Co Research Hardman & Co Video Event | Shield Therapeutics plc - Investor Forum 12-Aug-2021 / 07:25 GMT/BST Hardman & Co Video Event | Shield Therapeutics ...
    26.05.21 - DGAP
    Hardman & Co Research: Shield Therapeutics (STX): Accrufer launch on schedule
    Hardman & Co Research Hardman & Co Research: Shield Therapeutics (STX): Accrufer launch on schedule 26-May-2021 / 10:35 GMT/BST Hardman & Co Research: Accrufer ...
    02.02.21 - DGAP
    Edison Investment Research Limited: Shield Therapeutics (STX): Beefing up for the US opportunity
    Edison Investment Research Limited Edison Investment Research Limited: Shield Therapeutics (STX): Beefing up for the US opportunity 02-Feb-2021 / 08:00 GMT/BST London, ...
    06.01.21 - DGAP
    Hardman & Co Research: Shield Therapeutics (STX): Reassessing the US opportunity
    Hardman & Co Research Hardman & Co Research: Shield Therapeutics (STX): Reassessing the US opportunity 06-Jan-2021 / 07:15 GMT/BST Hardman & Co Research ...
    18.09.20 - DGAP
    Hardman & Co Research: Shield Therapeutics (STX): Optimism over US deal
    Hardman & Co Research Hardman & Co Research: Shield Therapeutics (STX): Optimism over US deal 18-Sep-2020 / 13:30 GMT/BST Hardman & Co Research: Optimism over ...
    11.05.20 - DGAP
    Hardman & Co Research: Shield Therapeutics (STX): Reassuring trading update
    Hardman & Co Research Hardman & Co Research: Shield Therapeutics (STX): Reassuring trading update 11-May-2020 / 13:15 GMT/BST Hardman & Co Res earch : Reassuring ...
    28.01.20 - DGAP
    Hardman & Co Research: Shield Therapeutics (STX): Good demand for Feraccru in Europe
    Hardman & Co Research Hardman & Co Research: Shield Therapeutics (STX): Good demand for Feraccru in Europe 28-Jan-2020 / 12:15 GMT/BST Hardman & Co Res earch ...
    14.01.20 - DGAP
    Hardman & Co Research: Shield Therapeutics (STX): Taking on China
    Hardman & Co Research Hardman & Co Research: Shield Therapeutics (STX): Taking on China 14-Jan-2020 / 07:15 GMT/BST Hardman & Co Res earch : Taking on China Shield ...
    30.10.19 - DGAP
    Hardman & Co Research: Shield Therapeutics (STX): More choice for clinicians and patients
    Hardman & Co Research Hardman & Co Research: Shield Therapeutics (STX): More choice for clinicians and patients 30-Oct-2019 / 07:30 GMT/BST Hardman & Co Res earch ...

    Newssuche

    Videos

    newspaper
    30.04.24 -9,41%
    Technical Trading: Sojabohnen Long bis Juli
    Sojabohnen Long Typ: Turbo Open End WKN: VX41AH Hebel: 5 Laufzeit: OpenEnd Einstieg: Market ... Mehr »